A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC

Trial Profile

A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs Alectinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALERT-lung
  • Most Recent Events

    • 13 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
    • 15 May 2018 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.
    • 15 May 2018 Planned primary completion date changed from 1 May 2022 to 1 Jun 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top